Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | F9 | P00740 | 3/20 | 0.42 |
| ▸ | CASR | P41180 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400241 | 0.89 | MAPT (0.52) | MAPTTP53SMN1; SMN2POLBF9 | |
| SCHEMBL2365024 | 0.82 | MAPT (0.51) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL2399017 | 0.79 | MAPT (0.46) | MAPTTP53SMN1; SMN2POLBCYP2C19 | |
| SCHEMBL2396935 | 0.79 | MAPT (0.47) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL2397327 | 0.77 | LIPG (0.47) | MAPTTP53SMN1; SMN2POLBUSP30 | |
| SCHEMBL2214186 | 0.77 | SMN1; SMN2 (0.46) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL2213974 | 0.76 | KLKB1 (0.59) | EPHX2MAPTTP53SMN1; SMN2POLB | |
| SCHEMBL2214252 | 0.76 | LMNA (0.45) | SMN1; SMN2POLBLMNAHPGDCYP2C9 | |
| SCHEMBL2399044 | 0.75 | NPC1 (0.46) | MAPTTP53POLB | |
| SCHEMBL2397972 | 0.75 | NOTUM (0.51) | LMNAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | claimed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | EPHX2 1245/4885MAPT 4877/4885TP53 721/4885 |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | CFTR, PKD1, PKD2 | EPHX2 3156/4885MAPT 4644/4885TP53 919/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | EPHX2 1245/4885MAPT 4877/4885TP53 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.